Literature DB >> 2317015

A disorder of axonal development, necrotizing myopathy, cardiomyopathy, and cataracts: a new familial disease.

G Lyon1, F Arita, E Le Galloudec, L Vallée, J P Misson, G Ferrière.   

Abstract

We report severe congenital encephalopathy and profound hypotonia associated with necrotizing myopathy, cardiomyopathy, and cataracts in 3 infants, including 2 sisters. Brain scans suggested agenesis of the corpus callosum. Neuropathological findings consisted of severe atrophy of the corpus callosum (not the usual agenesis with longitudinal callosal bundles), atrophy of the white matter, and absence of pyramidal tracts in the medulla. Multiple axonal swellings were present in the white matter and in Purkinje cells. Except for the corpus subthalamicum, gray matter structures were preserved. These findings are considered to be the expression of a primary disorder of axonal development leading to a reduction in interneuronal synaptic contacts. It is suggested that the anomaly may be due to an extension of the normal phenomenon of axonal elimination, related to a primary defect of the axonal cytoskeleton. The concept of a primary axonal disorder may also apply to other, mostly familial, conditions with progressive atrophy of the cerebral white matter and corpus callosum.

Entities:  

Mesh:

Year:  1990        PMID: 2317015     DOI: 10.1002/ana.410270216

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  2 in total

Review 1.  Absence makes the search grow longer.

Authors:  W B Dobyns
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

2.  Congenital hypertrophic cardiomyopathy, cataract, mitochondrial myopathy and defective oxidative phosphorylation in two siblings with Sengers-like syndrome.

Authors:  Eva Morava; Rob Sengers; Henk Ter Laak; Lambert Van Den Heuvel; Antoon Janssen; Frans Trijbels; Hans Cruysberg; Carolien Boelen; Jan Smeitink
Journal:  Eur J Pediatr       Date:  2004-05-27       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.